BACKGROUND: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder of the central nervous system (CNS). Its immunopathogenesis has been proposed to include early cerebrospinal fluid (CSF) lymphocytosis, subsequent CNS disease restriction and B cell mechanism predominance. There are limited data regarding T cell involvement in the disease. To contribute to the current knowledge, we investigated the complex system of chemokines and cytokines related to B and T cell functions in CSF and sera samples from anti-NMDAR encephalitis patients at different time-points of the disease. One patient in our study group had a long-persisting coma and underwent extraordinary immunosuppressive therapy. METHODS: Twenty-seven paired CSF/serum samples were collected from nine patients during the follow-up period (median 12 months, range 1-26 months). The patient samples were stratified into three periods after the onset of the first disease symptom and compared with the controls. Modified Rankin score (mRS) defined the clinical status. The concentrations of the chemokines (C-X-C motif ligand (CXCL)10, CXCL8 and C-C motif ligand 2 (CCL2)) and the cytokines (interferon (IFN)γ, interleukin (IL)4, IL7, IL15, IL17A and tumour necrosis factor (TNF)α) were measured with Luminex multiple bead technology. The B cell-activating factor (BAFF) and CXCL13 concentrations were determined via enzyme-linked immunosorbent assay. We correlated the disease period with the mRS, pleocytosis and the levels of all of the investigated chemokines and cytokines. Non-parametric tests were used, a P value <0.05 was considered to be significant. RESULTS: The increased CXCL10 and CXCL13 CSF levels accompanied early-stage disease progression and pleocytosis. The CSF CXCL10 and CXCL13 levels were the highest in the most complicated patient. The CSF BAFF levels remained unchanged through the periods. In contrast, the CSF levels of T cell-related cytokines (INFγ, TNFα and IL17A) and IL15 were slightly increased at all of the periods examined. No dynamic changes in chemokine and cytokine levels were observed in the peripheral blood. CONCLUSIONS: Our data support the hypothesis that anti-NMDAR encephalitis is restricted to the CNS and that chemoattraction of immune cells dominates at its early stage. Furthermore, our findings raise the question of whether T cells are involved in this disease.

Department of Immunology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Pediatric Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital 5 Uvalu 84 Prague 15006 Czech Republic

Zobrazit více v PubMed

Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65. doi: 10.1016/S1474-4422(12)70310-1. PubMed DOI PMC

Florance-Ryan N, Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescence. Curr Opin Pediatr. 2010;22(6):739–44. doi: 10.1097/MOP.0b013e3283402d2f. PubMed DOI

Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36. doi: 10.1002/ana.21050. PubMed DOI PMC

Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effect of antibodies. Lancet Neurol. 2008;7(12):1091–8. doi: 10.1016/S1474-4422(08)70224-2. PubMed DOI PMC

Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118:737–43. doi: 10.1007/s00401-009-0582-4. PubMed DOI PMC

Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinicalobservations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655–67. doi: 10.1093/brain/awq113. PubMed DOI PMC

Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood. 2013;121:2402–14. doi: 10.1182/blood-2012-09-378653. PubMed DOI PMC

Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversariers and collabolators. Ann N Y Acad Sci. 2010;1183:211–21. doi: 10.1111/j.1749-6632.2009.05133.x. PubMed DOI PMC

Carrette F, Surh CD. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol. 2012;24(3):209–17. doi: 10.1016/j.smim.2012.04.010. PubMed DOI PMC

Liba Z, Sebronova V, Komarek V, Sediva A, Sedlacek P. Prevalence and treatment of anti-NMDA receptor encephalitis. Lancet Neurol. 2013;12(5):424–5. doi: 10.1016/S1474-4422(13)70070-X. PubMed DOI

Leypoldt F, Höftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Jahn H, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurol. 2015;72:180–6. doi: 10.1001/jamaneurol.2014.2956. PubMed DOI PMC

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-MNDAR encephalitis. Lancet Neurol. 2011;10(1):63–74. doi: 10.1016/S1474-4422(10)70253-2. PubMed DOI PMC

Hachiya Y, Uruha A, Kasai-Yoshida E, Shimoda K, Sato-Shirai I, Kumada S, et al. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-live plasmablast. J Neuroimmunol. 2013;265(1-2):128–30. doi: 10.1016/j.jneuroim.2013.09.017. PubMed DOI

Graaf MT, Jongste AHC, Kraan J, Boonstra JG, Sillevis Smitt PA, Gratama JW. Flow cytometric characterization of cerebrospinal fluid cell. Cytometry B Clin Cytom. 2011;80(5):271–81. doi: 10.1002/cyto.b.20603. PubMed DOI

Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, et al. Chemokines inmultiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129:200–11. doi: 10.1093/brain/awh680. PubMed DOI

Kowarik MC, Cepok S, Sellner J, Grummel V, Weber MS, Korn T, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012;9:93. doi: 10.1186/1742-2094-9-93. PubMed DOI PMC

Esen N, Rainey-Barger EK, Huber AK, Blakely PK, Irani DN. Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13. Glia. 2014;62(9):1452–62. doi: 10.1002/glia.22692. PubMed DOI PMC

Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res. 2011;317(5):620–31. doi: 10.1016/j.yexcr.2010.12.017. PubMed DOI PMC

Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Verhulst SJ, Ransohoff RM. Expression of CXCR3 and its ligands CXCL9,-10 and -11 in paediatric opsoclonus-myoclonus syndrome. Clin Exp Immunol. 2013;172:427–36. doi: 10.1111/cei.12065. PubMed DOI PMC

Muehlinghaus G, Cigliano L, Huehn S, Peddinghaus A, Leyendeckers H, Hauser AE, et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood. 2005;105:3965–71. doi: 10.1182/blood-2004-08-2992. PubMed DOI

Phares TW, Stohlman SA, Hinton DR, Bergmann CC. Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis. J Virol. 2013;87:3382–92. doi: 10.1128/JVI.03307-12. PubMed DOI PMC

Peery HE, Day GS, Dunn S, Fritzler MJ, Pruss H, De Souza C, et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmune Rev. 2012;11(12):863–72. doi: 10.1016/j.autrev.2012.03.001. PubMed DOI

Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8(11):613–23. doi: 10.1038/nrneurol.2012.203. PubMed DOI

Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Colliver JA, Ness JM. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J Neuroinflammation. 2013;10:10. doi: 10.1186/1742-2094-10-10. PubMed DOI PMC

Patakas A, Benson RA, Withers DR, Conigliaro P, McInnes IB, Brewer JM, et al. Th17 effector cells support B cell responses outside of germinal centres. PLoS One. 2012;7 doi: 10.1371/journal.pone.0049715. PubMed DOI PMC

Uzawa A, Mori M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenic and therapeutic implications. Brain Pathol. 2014;24(1):67–73. doi: 10.1111/bpa.12097. PubMed DOI PMC

Utility of chemokines CCL2, CXCL8, 10 and 13 and interleukin 6 in the pediatric cohort for the recognition of neuroinflammation and in the context of traditional cerebrospinal fluid neuroinflammatory biomarkers